Proteasome Inhibition Reduces Donor-Specific Antibody Levels

Transplantation Proceedings

Volumn 41, Issue 1, 2009, Pages 105-107

  Everly, M J ^a   Everly, J J ^a   Susskind, B ^a   Brailey, P ^a   Arend, L J ^a   Alloway, R R ^a   Roy Chaudhury, P ^a   Govil, A ^a   Mogilishetty, G ^a   Rike, A H ^a   Cardi, M ^a   Wadih, G ^a   Brown, E ^a   Tevar, A ^a   Woodle, E S ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; HLA ANTIBODY;

ACUTE GRAFT REJECTION; ANTIBODY PRODUCTION; ARTICLE; CLINICAL ARTICLE; DIARRHEA; GASTROINTESTINAL TOXICITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; NAUSEA; OPPORTUNISTIC INFECTION; PLASMA CELL; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

BORONIC ACIDS; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; ISOANTIBODIES; KIDNEY TRANSPLANTATION; PANCREAS TRANSPLANTATION; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES;

EID: 60649114718     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.10.073     Document Type: Article

References (13)

1. Ramos E.J., Pollinger H.S., Stegall M.D., et al. The effect of desensitization protocols on human splenic B-cell populations in vivo. Am J Transplant 7 (2007) 402
2. Kyle R.A., and Rajkumar S.V. Multiple myeloma. N Engl J Med 351 (2004) 1860
3. Luo H., Wu Y., Qi S., et al. A proteasome inhibitor effectively prevents mouse heart allograft rejection. Transplantation 72 (2001) 196
4. Palombella V.J., Conner E.M., Fuseler J.W., et al. Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci U S A 95 (1998) 15671
5. Vanderlugt C.L., Rahbe S.M., Elliott P.J., et al. Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome PS-519. J Autoimmun 14 (2000) 205
6. Zollner T.M., Podda M., Pien C., et al. Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model. J Clin Invest 109 (2002) 671
7. Wang X., Luo H., Chen H., et al. Role of proteasomes in T cell activation and proliferation. J Immunol 160 (1998) 788
8. Solez K., Colvin R.B., Racusen L.C., et al. Banff'05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 7 (2007) 518
9. Racusen L.C., Colvin R.B., Solez K., et al. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 3 (2003) 708
10. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4 (2004) 349
11. Chauhan D., Catley L., Li G., et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 8 (2005) 407
12. Nencioni A., Garuti A., Schwarzenberg K., et al. Proteasome inhibitor-induced apoptosis in human monocyte-derived dendritic cells. Eur J Immunol 36 (2006) 681
13. Sun K., Welniak L.A., Panoskaltsis-Mortari A., et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci U S A 101 (2004) 8120